(Q33228693)

24 July 2017

title

Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology (English)

1 reference

24 July 2017

Oliver Kayser

2

0 references

author name string

Norma Hernández-Trejo

series ordinal

1

1 reference

24 July 2017

Hartwig Steckel

series ordinal

3

1 reference

24 July 2017

Rainer H Müller

series ordinal

4

1 reference

24 July 2017

publication date

1 September 2005

1 reference

Journal of Drug Targeting

24 July 2017

published in

1 reference

24 July 2017

volume

13

1 reference

24 July 2017

issue

8-9

1 reference

24 July 2017

page(s)

499-507

1 reference

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Selective deposition of inhaled aerosols to mechanically ventilated rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Production and characterization of a budesonide nanosuspension for pulmonary administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860500353245

10.1080/10611860500353245

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference